CNS Pharmaceuticals, Inc. Logo

CNS Pharmaceuticals, Inc.

Biotech developing drugs that cross the blood-brain barrier for brain and CNS cancers.

CNSP | US

Overview

Corporate Details

ISIN(s):
US18978H1023
LEI:
Country:
United States of America
Address:
2100 WEST LOOP SOUTH, 77027 HOUSTON
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

CNS Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing novel treatments for primary and metastatic cancers of the brain and central nervous system. The company's primary therapeutic focus is on glioblastoma multiforme (GBM), an aggressive and often incurable form of brain cancer. Its development pipeline features anti-cancer drug candidates, including its lead drug Berubicin, which are designed to cross the blood-brain barrier to effectively target brain malignancies. CNS Pharmaceuticals aims to advance transformative therapies through pioneering research to improve patient outcomes.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all CNS Pharmaceuticals, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for CNS Pharmaceuticals, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for CNS Pharmaceuticals, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Celltrion, Inc. Logo
A biopharma pioneer developing biosimilars and novel drugs for immunology and oncology.
South Korea
068270
Celltrion Pharm Inc. Logo
South Korea
068760
Develops bone grafts, artificial joints, and enzymes for the biopharmaceutical sector.
South Korea
049180
Celon Pharma S.A. Logo
Researches, develops, and markets innovative drugs for oncology and neurology.
Poland
CLN
Celularity Inc Logo
Develops off-the-shelf cell therapies from placentas for cancer and aging-related diseases.
United States of America
CELU
Centessa Pharmaceuticals plc Logo
Develops medicines for sleep-wake disorders, hemophilia, and other unmet medical needs.
United States of America
CNTA
Century Therapeutics, Inc. Logo
Developing iPSC-derived, off-the-shelf cell therapies for cancer & autoimmune diseases.
United States of America
IPSC
Cereno Scientific AB Logo
Develops epigenetic therapies for rare cardiovascular and pulmonary diseases.
Sweden
CRNO
CERO THERAPEUTICS HOLDINGS, INC. Logo
Develops engineered T-cell immunotherapies for cancer using its proprietary CER platform.
United States of America
CERO
CERUS CORP Logo
Develops pathogen reduction technology to safeguard the global blood supply for healthcare providers.
United States of America
CERS

Talk to a Data Expert

Have a question? We'll get back to you promptly.